Servier Bio-innovation Llc

This study tests a new drug called S095029 combined with pembrolizumab in people with advanced stomach or esophageal cancer that has a specific genetic feature (MSI-H/dMMR). The goal is to see if the combination is safe and can shrink tumors. About 48 participants will take part,…

This study tests three new drug combinations for people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. The goal is to see if adding another immunotherapy drug to the standard anti-PD1 treatment can better control the cancer. A…